PANKAJ VATS

PANKAJ VATS

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSunita Shankar
Sunita Shankar
JTJean Ching-Yi Tien
Jean Ching-Yi Tien
RSRonald F. Siebenaler
Ronald F. Siebenaler
SCSeema Chugh
Seema Chugh
VDVijaya L. Dommeti
Vijaya L. Dommeti
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
Both KRAS and EGFR are essential mediators of pancreatic cancer development and interact with Argonaute 2 (AGO2) to perturb its function. Here, in a mouse model of mutant KRAS-driven pancreatic cancer, loss of AGO2 allows precursor lesion (PanIN) formation yet prevents progression to pancreatic ductal adenocarcinoma (PDAC). Precursor lesions with AGO2 ablation undergo oncogene-induced senescence with altered microRNA expression and EGFR/RAS signaling, bypassed by loss of p53. In mouse and human pancreatic tissues, PDAC progression is associated with increased plasma membrane localization of RAS/AGO2. Furthermore, phosphorylation of AGO2Y393 disrupts both the wild-type and oncogenic KRAS-AGO2 interaction, albeit under different conditions. ARS-1620 (G12C-specific inhibitor) disrupts the KRASG12C-AGO2 interaction, suggesting that the interaction is targetable. Altogether, our study supports a biphasic model of pancreatic cancer development: an AGO2-independent early phase of PanIN formation reliant on EGFR-RAS signaling, and an AGO2-dependent phase wherein the mutant KRAS-AGO2 interaction is critical for PDAC progression.

9 August 2022 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
GCGiovanna Carpi
Giovanna Carpi
LGLev Gorenstein
Lev Gorenstein
THTimothy T Harkins
Timothy T Harkins
MSMehrzad Samadi
Mehrzad Samadi
PVPANKAJ VATS
PANKAJ VATS
As recently demonstrated by the COVID-19 pandemic, large-scale pathogen genomic data are crucial to characterize transmission patterns of human infectious diseases. Yet, current methods to process raw sequence data into analysis-ready variants remain slow to scale, hampering rapid surveillance efforts and epidemiological investigations for disease control. Here, we introduce an accelerated, scalable, reproducible, and cost-effective framework for pathogen genomic variant identification and present an evaluation of its performance and accuracy across benchmark datasets of Plasmodium falciparum malaria genomes. We demonstrate superior performance of the GPU framework relative to standard pipelines with mean execution time and computational costs reduced by 27× and 4.6×, respectively, while delivering 99.9% accuracy at enhanced reproducibility.

31 May 2023 in Neoplasia
Verified
Journal Article
Open access
CKChandan Kumar-Sinha
Chandan Kumar-Sinha
PVPANKAJ VATS
PANKAJ VATS
NTNguyen Tran
Nguyen Tran
DRDan R. Robinson
Dan R. Robinson
VGValerie Gunchick
Valerie Gunchick
VSVaibhav Sahai
Vaibhav Sahai
Biliary tract cancers (BTCs) including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are rare but aggressive malignancies with few effective standard of care therapies. We implemented integrative clinical sequencing of advanced BTC tumors from 124 consecutive patients who progressed on standard therapies (N=92 with MI-ONCOSEQ and N=32 with commercial gene panels) enrolled between 2011-2020. Genomic profiling of paired tumor and normal DNA and tumor transcriptome (RNA) sequencing identified actionable somatic and germline genomic alterations in 54 patients (43.5%), and potentially actionable alterations in 79 (63.7%) of the cohort. Of these, patients who received matched targeted therapy (22; 40.7%) had a median overall survival of 28.1 months compared to 13.3 months in those who did not receive matched targeted therapy (32; P < 0.01), or 13.9 months in those without actionable mutations (70; P < 0.01). Additionally, we discovered recurrent activating mutations in FGFR2, and a novel association between KRAS and BRAF mutant tumors with high expression of immune modulatory protein NT5E (CD73) that may represent novel therapeutic avenues. Overall, the identification of actionable/ potentially actionable aberrations in a large proportion of cases, and improvement in survival with precision oncology supports molecular analysis and clinical sequencing for all patients with advanced BTC.

1 August 2013 in Translational Oncology
Verified
Journal Article
Open access
RMRohit Mehra
Rohit Mehra
SDSaravana M. Dhanasekaran
Saravana M. Dhanasekaran
NPNallasivam Palanisamy
Nallasivam Palanisamy
PVPANKAJ VATS
PANKAJ VATS
XCXuhong Cao
Xuhong Cao
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
E26 transformation-specific (ETS) transcription factors are known to be involved in gene aberrations in various malignancies including prostate cancer; however, their role in melanoma oncogenesis has yet to be fully explored. We have completed a comprehensive fluorescence in situ hybridization (FISH)-based screen for all 27 members of the ETS transcription factor family on two melanoma tissue microarrays, representing 223 melanomas, 10 nevi, and 5 normal skin tissues. None of the melanoma cases demonstrated ETS fusions; however, 6 of 114 (5.3%) melanomas were amplified for ETV1 using a break-apart FISH probe. For the six positive cases, locus-controlled FISH probes revealed that two of six cases were amplified for the ETV1 region, whereas four cases showed copy gains of the entire chromosome 7. The remaining 26 ETS family members showed no chromosomal aberrations by FISH. Quantitative polymerase chain reaction showed an average 3.4-fold (P value = .00218) increased expression of ETV1 in melanomas, including the FISH ETV1-amplified cases, when compared to other malignancies (prostate, breast, and bladder carcinomas). These data suggest that a subset of melanomas overexpresses ETV1 and amplification of ETV1 may be one mechanism for achieving high gene expression.

6 July 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Khushboo Borah SlaterKhushboo Borah Slater
Khushboo Borah Slater
JKJacque-Lucca Kearney
Jacque-Lucca Kearney
RBRuma Banerjee
Ruma Banerjee
PVPANKAJ VATS
PANKAJ VATS
HWHuihai Wu
Huihai Wu
JMJohnjoe Mcfadden
Johnjoe Mcfadden
Leprosy, caused by Mycobacterium leprae, has plagued humanity for thousands of years and continues to cause morbidity, disability and stigmatization in two to three million people today. Although effective treatment is available, the disease incidence has remained approximately constant for decades so new approaches, such as vaccine or new drugs, are urgently needed for control. Research is however hampered by the pathogen’s obligate intracellular lifestyle and the fact that it has never been grown in vitro. Consequently, despite the availability of its complete genome sequence, fundamental questions regarding the biology of the pathogen, such as its metabolism, remain largely unexplored. In order to explore the metabolism of the leprosy bacillus with a long-term aim of developing a medium to grow the pathogen in vitro, we reconstructed an in silico genome scale metabolic model of the bacillus, GSMN-ML. The model was used to explore the growth and biomass production capabilities of the pathogen with a range of nutrient sources, such as amino acids, glucose, glycerol and metabolic intermediates. We also used the model to analyze RNA-seq data from M. leprae grown in mouse foot pads, and performed Differential Producibility Analysis to identify metabolic pathways that appear to be active during intracellular growth of the pathogen, which included pathways for central carbon metabolism, co-factor, lipids, amino acids, nucleotides and cell wall synthesis. The GSMN-ML model is thereby a useful in silico tool that can be used to explore the metabolism of the leprosy bacillus, analyze functional genomic experimental data, generate predictions of nutrients required for growth of the bacillus in vitro and identify novel drug targets. Mycobacterium leprae, the obligate human pathogen is uncultivable in axenic growth medium, and this hinders research on this pathogen, and the pathogenesis of leprosy. The development of novel therapeutics relies on the understanding of growth, survival and metabolism of this bacterium in the host, the knowledge of which is currently very limited. Here we reconstructed a metabolic network of M. leprae- GSMN-ML, a powerful in silico tool to study growth and metabolism of the leprosy bacillus. We demonstrate the application of GSMN-ML to identify the metabolic pathways, and metabolite classes that M. leprae utilizes during intracellular growth.

27 July 2025 in bioRxiv
Verified
Preprint
Open access
TZTong Zhu
Tong Zhu
PVPANKAJ VATS
PANKAJ VATS
SOSeth Onken
Seth Onken
ADAl Dunstan
Al Dunstan
BZBabak Zamirai
Babak Zamirai
MSMehrzad Samadi
Mehrzad Samadi
Next-generation sequencing (NGS) has transformed genomics, enabling breakthroughs in biotechnology, healthcare, and pharmaceuticals. However, exponential data growth-outpacing Moore’s Law-presents critical computational challenges for secondary analysis. We introduce Parabricks, a freely accessible, GPU-accelerated software suite supporting diverse workflows, including wholegenome, exome, transcriptome, and methylation analysis. Compatible across major short read and long read sequencing platforms, it reduces processing time from hours to minutes while maintaining concordance with established standards, this acceleration translates to significant cost savings. Deployable on-premises or through cloud platforms, Parabricks ensures scalable, genomic processing. Integrated AI-driven workflows and deep learning models further enhance precision, offering a universal solution for high-throughput genomic research and clinical diagnostics.